Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmaTher Holdings Ltd ( (TSE:PHRM) ) just unveiled an update.
PharmaTher Holdings Ltd. has announced the advancement of its ketamine transdermal patch as a non-opioid pain relief solution, following the FDA approval of its IV ketamine product, KETARx™. This initiative aligns with the FDA’s national priority to address the opioid epidemic by providing a safe, effective alternative to opioids, targeting the substantial U.S. pain management market. The ketamine patch aims to deliver controlled analgesia for acute and chronic pain, potentially capturing a significant market share as a first-in-class solution. PharmaTher’s strategic positioning leverages its existing FDA-approved platform and aims to accelerate development through the FDA’s priority programs, potentially transforming pain management practices and offering new opportunities in mental health treatment.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on the pharmaceutical potential of ketamine, particularly through its FDA-approved product KETARx™ for anesthesia and sedation in surgical and diagnostic procedures. The company is also exploring additional indications and developing a ketamine patch for pain and mental health conditions.
Average Trading Volume: 236,567
Technical Sentiment Signal: Buy
Current Market Cap: C$34.08M
Learn more about PHRM stock on TipRanks’ Stock Analysis page.